Share：
Share this content in WeChat
X
[Chinese][PDF]72078
• Review •
Progress of quantitative dynamic contrast-enhanced magnetic resonance imaging and in diagnosis and evaluation on therapeutic response of prostate cancer
LU Yang  BO Gen-ji 

DOI:10.3969/j.issn.1674-8034.2015.10.016.


[Abstract] Quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can reflect the hemodynamics information such as angiogenesis and the permeability of capillary, which may be of great help in the diagnosis and assessment of therapeutic response in prostate cancer. This article is to make a review about the basic principle of the quantitative analysis of DCE-MRI andits application in the diagnosis and assessment of therapeutic response in prostate cancer.
[Keywords] Magnetic resonance imaging；Dynamic contrast enhanced；Prostatic neoplasms

LU Yang Department of Medical Imaging, the First Pople’s Hospital of Huaian, Affiliated to Nanjing Medical University, Huai’an 223300, Jiangsu Province, China

BO Gen-ji* Department of Medical Imaging, the First Pople’s Hospital of Huaian, Affiliated to Nanjing Medical University, Huai’an 223300, Jiangsu Province, China

*Correspondence to: Bo GJ, E-mail: hybgj0451@163.com

Conflicts of interest   None.

Received  2015-04-03
Accepted  2015-06-07
DOI: 10.3969/j.issn.1674-8034.2015.10.016
DOI:10.3969/j.issn.1674-8034.2015.10.016.

[1]
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30.
[2]
陈敏，李春媚.前列腺癌磁共振成像诊断要点与临床治疗方案选择.磁共振成像, 2011, 2(3): 225-232.
[3]
Zhang X, Quan X, Lu S, et al. The clinical value of dynamic contrast-enhanced magnetic resonance imaging at 3.0T to detect prostate cancer. J Int Med Res, 2014, 42(5): 1077-1084.
[4]
Nishida S, Kinoshita H, Mishima T, et al. Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging. Int J Urol, 2011, 18(9): 653-658.
[5]
Turkbey B, Choyke PL. Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol, 2012, 22(4): 310-315.
[6]
Turkbey B, Bernardo M, Merino MJ, et al. MRI of localized prostate cancer: coming of age in the PSA era. Diagn Interv Radiol, 2012, 18(1): 34-45.
[7]
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995, 1(1): 27-31.
[8]
Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol, 2000, 7(10): 800-811.
[9]
Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol, 1993, 24(2): 220-226.
[10]
Pallares J, Rojo F, Iriarte J, et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol, 2006, 21(8): 857-865.
[11]
Taylor JS, Tofts PS, Port R, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging, 1999, 10(6): 903-907.
[12]
Khalifa F, Soliman A, El-Baz A, et al. Models and methods for analyzing DCE-MRI: A review. Med Phys, 2014, 41(12): 124301.
[13]
王世威，喻迎星，潘智勇,等. 3.0 T定量动态对比增强MRI对中央区前列腺癌的应用价值研究.医学影像学杂志, 2014, 24(5): 824-827.
[14]
景国东，汪剑，陈录广,等. 3.0 T动态增强MRI在前列腺癌诊断中的价值.放射学实践, 2014, 29(5): 482-486.
[15]
何为，刘毅，刘剑羽,等. 3.0 T MR动态增强扫描定量分析诊断前列腺癌的价值.中华放射学杂志, 2014, 48(3): 215-218.
[16]
李春媚，陈敏，李飒英,等. 3.0 T MR动态增强扫描定量分析诊断前列腺癌的初步研究.中华放射学杂志, 2011, 45(1): 50-54.
[17]
Kozlowski P, Chang SD, Jones EC, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology. J Magn Reson Imaging, 2006, 24(1): 108-113.
[18]
Langer DL, van der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2009, 30(2): 327-334.
[19]
Schlemmer HP, Merkle J, Grobholz R, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens. Eur Radiol, 2004, 14(2): 309-317.
[20]
Kozlowski P, Chang SD, Meng R, et al. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy. Magn Reson Imaging, 2010, 28(5): 621-628.
[21]
Chen YJ, Chu WC, Pu YS, et al. Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. J Magn Reson Imaging, 2012, 36(4): 912-919.
[22]
Rosenkrantz AB, Sabach A, Babb JS, et al. Prostate cancer: comparison of dynamic contrast-enhanced MRI techniques for localization of peripheral zone tumor. AJR Am J Roentgenol, 2013, 201(3): W471-478.
[23]
刘会佳，赵娓娓，任芳,等. 3.0 T动态增强磁共振对前列腺癌的定量分析研究.放射学实践, 2014, 29(5): 477-481.
[24]
朱海滨，刘婧，蔡文超,等.前列腺癌MRI动态增强定量参数Ktrans值与Gleason评分的相关性研究.中国医学影像学杂志, 2012, 20(7): 481-484.
[25]
Vos EK, Litjens GJ, Kobus T, et al. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3.0 T. Eur Urol, 2013, 64(3): 448-455.
[26]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2): 228-247.
[27]
Dahut WL, Madan RA, Karakunnel JJ, et al. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int, 2013, 111(8): 1269-1280.
[28]
Cyran CC, Paprottka PM, Schwarz B, et al. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. AJR Am J Roentgenol, 2012, 198(2): 384-391.
[29]
Sampath D, Oeh J, Wyatt SK, et al. Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. Neoplasia, 2013, 15(7): 694-711.
[30]
O'Connor JP, Jackson A, Parker GJ, et al. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol, 2012, 9(3): 167-177.
[31]
Alonzi R, Padhani AR, Taylor NJ, et al. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys, 2011, 80(3): 721-727.
[32]
Barrett T, Gill AB, Kataoka MY, et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med, 2012, 67(3): 778-785.
[33]
Durmus T, Vollnberg B, Schwenke C, et al. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin, 2013, 185(9): 862-868.
[34]
李亮，冯朝燕，Yu J,等. 2012年北美放射学年会前列腺影像学最新研究进展.磁共振成像, 2013, 4(3): 166-171.

PREV The research status and application prospect of magnetic resonance spectrum in alcohol addicts
NEXT The effect caused by interictal epileptic discharges on mesial temporal lobe epilepsy brain networks
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn